Practical classification of triple-negative breast cancer: intratumoral heterogeneity mechanisms of drug resistance and novel therapies

摘要

Transcriptomic-based and gene expression-based subtypes of triple-negative breast cancer (TNBC) according to PAM5028 (a) and defined by Lehmann et al.20,22 (b and d), Curtis et al.24 (c), Burstein et al.23 (e), and Jiang et al.25 (f). BLIA basal-like immune-activated, BLIS basal-like immunosuppressed, BL1 basal-like 1, BL2 basal-like 2, IM immunomodulatory, IntClust integrative clusters, LAR luminal androgen receptor, M mesenchymal, MES mesenchymal, MSL mesenchymal stem-like, UNS unstable. Figures was generated by reanalysis of publicly available studies and open-source platforms (cBioPortal: https://www.cbioportal.org).